Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Manitoba

$46,000.00

Immunomodulatory effects of berenil, a trypanocidal agent

FY 2009-10

Summary
African trypanososomiasis, caused by several species of the extracellular protozoan parasite belonging to the genus Trypanosoma, is severe and often fatal disease of humans and livestock. Diminazene aceturate (Berenil) is the drug of choice for treatment of African trypanosomiasis in animals. First described in the mid 1950s, a substantial body of data has been generated on various pharmacological aspects of the compound. However, it is not known whether Berenil mediates its anti-parasitic effects exclusively by destroying blood stream forms of the parasite or by combining its trypanocidal activity with immuno-modulatory effects. An additional immuno-modulatory effect seems plausible in view of the fact that certain antimicrobial agents, originally thought to have only anti-microbial effects have now been shown to exert potent immunomodulatory activities. Furthermore, an exclusive trypanolytic activity does not completely explain certain observations in treated animals. For example, parasitemia in cattle treated with Berenil falls sharply to undetectable level within 8 hr post treatment. In contrast, parasites are still detected after 24 hr in blood samples from treated animals that are incubated at 37 oC, strongly suggesting that destruction of parasites is not the only mechanisms of action of the drug. Recently, we found that treatment of infected highly susceptible BALB/c mice with Berenil leads to complete clearance of parasitemia and a concomitant decrease in the production of IFN-gamma and other proinflammatory cytokines including IL-1ß, IL-6, IL-12 and TNF-alpha. We have confirmed that Berenil potently inhibits LPS-induced production of proinflammatory cytokines by macrophages in vitro. The overarching goal of the studies proposed here is to investigate the cellular and molecular mechanisms of anti-inflammatory properties of Berenil in vitro and in vivo. We believe these studies will elucidate the immunomodulatory and anti-inflammatory effects of Berenil at the molecular and cellular levels and could also help explain the mechanisms of cellular toxicity of Berenil. In addition, they will provide potential selective targets for Berenil and other related drugs for the purposes of controlling inflammatory processes.
Program
Discovery Grants Program - Individual
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
288314-2009
Name nom
Uzonna, Jude
Department département
Immunology
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
46000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
5
Application title
Immunomodulatory effects of berenil, a trypanocidal agent
Keyword
NA
Application summary
African trypanososomiasis, caused by several species of the extracellular protozoan parasite belonging to the genus Trypanosoma, is severe and often fatal disease of humans and livestock. Diminazene aceturate (Berenil) is the drug of choice for treatment of African trypanosomiasis in animals. First described in the mid 1950s, a substantial body of data has been generated on various pharmacological aspects of the compound. However, it is not known whether Berenil mediates its anti-parasitic effects exclusively by destroying blood stream forms of the parasite or by combining its trypanocidal activity with immuno-modulatory effects. An additional immuno-modulatory effect seems plausible in view of the fact that certain antimicrobial agents, originally thought to have only anti-microbial effects have now been shown to exert potent immunomodulatory activities. Furthermore, an exclusive trypanolytic activity does not completely explain certain observations in treated animals. For example, parasitemia in cattle treated with Berenil falls sharply to undetectable level within 8 hr post treatment. In contrast, parasites are still detected after 24 hr in blood samples from treated animals that are incubated at 37 oC, strongly suggesting that destruction of parasites is not the only mechanisms of action of the drug. Recently, we found that treatment of infected highly susceptible BALB/c mice with Berenil leads to complete clearance of parasitemia and a concomitant decrease in the production of IFN-gamma and other proinflammatory cytokines including IL-1ß, IL-6, IL-12 and TNF-alpha. We have confirmed that Berenil potently inhibits LPS-induced production of proinflammatory cytokines by macrophages in vitro. The overarching goal of the studies proposed here is to investigate the cellular and molecular mechanisms of anti-inflammatory properties of Berenil in vitro and in vivo. We believe these studies will elucidate the immunomodulatory and anti-inflammatory effects of Berenil at the molecular and cellular levels and could also help explain the mechanisms of cellular toxicity of Berenil. In addition, they will provide potential selective targets for Berenil and other related drugs for the purposes of controlling inflammatory processes.
University of Manitoba - $46,000 Grant (2009-10) | Canada Spends